Pasar al contenido principal

PROSTATEPREDICT. DESARROLLO DE UNA PRUEBA DE PRONÓSTICO PARA PREDECIR LA PROBABILIDAD DE ENFERMEDAD AGRESIVA DESPUÉS DE LA CIRUGÍA

IPT-2012-1311-300000

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Nacional de Cooperación Público-Privada
Subprograma Subprograma INNPACTO
Convocatoria INNPACTO
Año convocatoria 2012
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Secretaría de Estado de Investigación, Desarrollo e Innovación
Centro beneficiario ALTHIA HEALTH SL
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multiple immunofluorescence assay identifies upregulation of Active β-catenin in prostate cancer

  • Puig Rosell, Pere
  • Erill, Nadina|||0000-0003-3530-2669
  • Terricabras, Marta
  • Subirana, Isaac|||0000-0003-1676-0197
  • González-García, Judit
  • Asensi-Puig, Adrià
  • Donovan, Michael J.
  • Mengual, Lourdes
  • Agulló-Ortuño, M. Teresa
  • Olivan, Mireia|||0000-0002-8464-0827
  • Alcaraz, Antonio|||0000-0003-2612-5250
  • Lopez-Martin, Jose A.|||0000-0001-7530-3207
  • de Torres, Inés|||0000-0002-5495-9140
  • Rodríguez-Peralto, José Luis
  • Rodríguez Antolín, Alfredo
  • Morote Robles, Juan|||0000-0002-2168-323X
  • González-Rumayor, Víctor|||0000-0002-3205-1502
To apply a systems pathology-based approach to the quantification of nuclear Active β-catenin and human leukocyte antigen class I, and assess the biomarker involvement in a cohort of prostate tumor patients. The systems pathology approach applied allows a precise quantification of the marker expression in the different cell compartments as well as the determination of the areas that coexpress two markers. Our data shows that the accumulation of β-catenin in the nuclear compartment is significantly decreased in the adjacent normal areas when compared to tumor of the same patients (p < 0.001). In conclusion, the application of this novel multiple immunofluorescence assay demonstrates that the upregulation of Active β-catenin is a relatively common feature of prostate tumor development, and further supports the activation of the Wnt/β-catenin pathway in prostate cancer progression. The online version of this article (10.1186/s13104-019-4100-z) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Molecular Markers for Prostate Cancer in Formalin-Fixed Paraffin-Embedded Tissues

  • Sequeiros, Tamara|||0000-0002-0908-2263
  • García, Marta|||0000-0001-5155-4730
  • Montes, Melania|||0000-0002-4268-6608
  • Olivan, Mireia|||0000-0002-8464-0827
  • Rigau, Marina|||0000-0002-1691-454X
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • de Torres, Inés|||0000-0002-5495-9140
  • Morote Robles, Juan|||0000-0002-2168-323X
  • Reventós Puigjaner, Jaume|||0000-0002-2154-6593
  • Doll, Andreas|||0000-0001-8965-8682
Prostate cancer (PCa) is the most frequently diagnosed type of cancer in developed countries. The decisive method of diagnosis is based on the results of biopsies, morphologically evaluated to determine the presence or absence of cancer. Although this approach leads to a confident diagnosis in most cases, it can be improved by using the molecular markers present in the tissue. Both miRNAs and proteins are considered excellent candidates for biomarkers in formalin-fixed paraffin-embedded (FFPE) tissues, due to their stability over long periods of time. In the last few years, a concerted effort has been made to develop the necessary tools for their reliable measurement in these types of samples. Furthermore, the use of these kinds of markers may also help in establishing tumor grade and aggressiveness, as well as predicting the possible outcomes in each particular case for the different treatments available. This would aid clinicians in the decision-making process. In this review, we attempt to summarize and discuss the potential use of microRNA and protein profiles in FFPE tissue samples as markers to better predict PCa diagnosis, progression, and response to therapy.